Search Results
Oct 20, 2025, 08:00 ET RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
mg, once daily, compared to adalimumab (HUMIRA®) 40 mg, every other week, in adult patients with moderate to severe rheumatoid arthritis (RA) on a stable background of methotrexate (MTX) who had an inadequate response or intolerance to a TNF inhibitor (TNFi) other than adalimumab.1
More news about: AbbVie
Oct 20, 2025, 07:43 ET Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London
CGT. Panelists include: Laura Stoppel, Partner on the Investment Team, RA Capital Management Hongbo Lu, Founder and Managing Partner, NextBio Capital Daniela Couto, General
More news about: GenScript Biotech Corporation
Oct 17, 2025, 01:32 ET FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States
studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of adalimumab-aaty with abatacept or anakinra is not recommended in patients with RA. A higher rate of serious
More news about: Celltrion USA
Oct 16, 2025, 14:28 ET RAAP: Colorado PDAB Chooses Politics Over Patent Access
reimbursement decision regarding "Enbrel." (Enbrel is a biologic primarily used to treat signs and symptoms of moderate to severe rheumatoid arthritis (RA)).
More news about: Rare Access Action Project (RAAP)
Oct 14, 2025, 08:00 ET Radence expands concierge membership to detect and prevent disease before it occurs
Radence is backed by RA Ventures, the health care incubator of RA Capital Management, and a team of more than 50 MDs and PhDs dedicated to funding the development of novel medicines and tests. Radence draws on the research and predictive power of RA Capital's TechAtlas division, which
More news about: Radence
Oct 13, 2025, 11:11 ET PANTHERx® Rare Selected by Chiesi for the Distribution of MYCAPSSA®
trademark owned by the Chiesi Group.Chiesi Total CareSM is a service mark of CHIESI FARMACEUTICI S.p.A.All rights reserved. PP-RA-01192 V1.0 09/2025
More news about: PANTHERx Rare Pharmacy
Oct 13, 2025, 11:00 ET PEGATRON Powers the Future of Data Centers with Advanced OCP Solutions at OCP Global Summit 2025
At the forefront of PEGATRON's lineup is the RA4802-72N2, featuring the NVIDIA GB300 NVL72 platform with 72
More news about: PEGATRON CORPORATION
Oct 13, 2025, 10:57 ET U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.
More news about: AbbVie
Oct 13, 2025, 03:00 ET MediaTek y Airoha presentan la primera plataforma de fibra óptica del mundo impulsada por IA
utilizan anualmente los chips del Grupo MediaTek: desde smartphones, auriculares, relojes inteligentes y gafas de realidad aumentada/realidad virtual (RA/RV) hasta altavoces domésticos inteligentes, altavoces Bluetooth portátiles, televisores inteligentes, decodificadores, sistemas de cine en casa, portátiles
More news about: Airoha Technology
Oct 13, 2025, 03:00 ET MediaTek et Airoha présentent la première plateforme de passerelle fibre optique au monde alimentée par l'IA
terminaux utilisent chaque année les puces du groupe MediaTek, qu'il s'agisse de smartphones, d'oreillettes, de montres intelligentes, de lunettes RA/RV, d'enceintes domestiques intelligentes, d'enceintes Bluetooth portables, de téléviseurs intelligents, de décodeurs, de home cinémas, d'ordinateurs portables
More news about: Airoha Technology
Oct 07, 2025, 11:50 ET Rheumatoid Arthritis Drugs Market Size to Reach US$ 56.62 Billion by 2033 with 6.8% CAGR - Analysis by DataM Intelligence
projected to reach US$56.62 billion by 2033, growing at a CAGR of 6.8%. Increased awareness of RA and its early symptoms drives market growth, emphasizing early diagnosis and treatment to prevent joint damage. RA is a progressive disease influenced by genetics, environment, and hormones, more common in women.
More news about: DataM Intelligence 4 Market Research LLP
Oct 07, 2025, 08:00 ET RheumaGen and SiVEC Biotechnologies Announce CGT Partnership and In Vivo Program to Cure Common Autoimmune Diseases
candidate, RG0401, targets 10-20% of RA patients who are refractory or treatment-resistant and suffer substantial unmet need. The Company is currently conducting RG0401 IND-enabling studies and plans to begin the Phase I clinical trial in 2027. RG0401 aims to cure refractory RA by treating its HLA source. With
More news about: RheumaGen, Inc.
Oct 06, 2025, 14:29 ET Bermuda Targets Global Tech Leaders Following Google's Two Subsea Cable Announcements at Submarine Networks World 2025
Regulatory Authority of Bermuda (RA) showcased Bermuda's growing role as a strategic hub for transatlantic cable development. In tandem with a business attraction mission to Hong Kong,
More news about: Bermuda Business Development Agency
Oct 02, 2025, 09:32 ET Bosch Power Tools Expands 18V System with New Tools Designed for Performance, Precision and Ease of Use
Palm Router Chip Protection Guard (RA1130) Enhanced dust extraction – Deflects palm router chips into the Bosch dust extraction hood RA1132 (sold separately)
More news about: Bosch Power Tools
Oct 02, 2025, 08:30 ET Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States
treatment of: Rheumatoid Arthritis (RA): Adult patients with moderately to severely active RA who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
More news about: Celltrion
Oct 01, 2025, 08:00 ET RheumaGen Announces Oral Presentation on HLA Gene-Editing Preclinical Data for Lead Autoimmune Disease Program at ACR Convergence 2025
Class II HLA-DRB1*04:01, the strongest genetic risk factor for rheumatoid arthritis (RA). The results demonstrate that RheumaGen's approach has the potential to be used as a gene therapy to safely halt the progression of RA in patients carrying this allele variant.
More news about: RheumaGen, Inc.
Oct 01, 2025, 04:39 ET India Ratings Affirms Star Health Insurance Company's Rating at 'IND AA+' with a Stable Outlook
Star Health and Allied Insurance Company Limited (Star Health), India's leading standalone health insurer, announced that India Ratings and Research (Ind-Ra) has affirmed the Company's rating at at 'IND AA+' with a Stable outlook, while also reaffirming the subordinated debt rating at 'IND AA' with a Stable
More news about: Star Health and Allied Insurance
Oct 01, 2025, 04:36 ET Huawei publica el informe técnico sobre la tecnología avanzada Wi-Fi 7 para Europa
usuarios VIP. En conjunto, estas innovaciones crean una red de oficina de 10 Gbps para entornos empresariales de vanguardia, como flujos de trabajo con RA. Los espacios inteligentes se crean mediante la integración de Wi-Fi, sensores e IoT. El sensor Wi-Fi detecta la presencia
More news about: Huawei
Sep 30, 2025, 08:00 ET Immuno-Oncology 360º Announces 2026 Featured Speakers and Key Topics for the 12th Annual Meeting in Boston
MPM BioImpact NCI Novartis OrbiMed RA Capital Regeneron Stanford University Stifel
More news about: Immuno-Oncology 360º
Sep 30, 2025, 07:00 ET RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for Innovative Healthcare Companies
at RA Capital. "With the recent launch of our Structured Capital strategy, RA Capital's financing capabilities now include flexible equity, debt, royalty, and hybrid solutions designed to meet the needs of innovative, best-in-class healthcare companies like ARS Pharma." RA Capital's
More news about: RA Capital Management, LP
Sep 29, 2025, 11:21 ET Contagem regressiva para o verão: é hora de cuidar da pele para chegar com tudo no período de festas e férias
poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol. 2010 Mar;62(3):448-62.6. Weiss RA et al. Dermatol Surg. 2016 Jun;42(6):699-709 7. Bonhert K, et al. Randomized, Controlled, Multicentered, Double-Blind
More news about: Galderma
Sep 29, 2025, 07:02 ET Garmin named 2025 Manufacturer of the Year by NMEA for 11th straight year
Fusion® Apollo™ RA770 Marine Stereo Premium audio source unit with built-in Wi-Fi®. Garmin has earned
More news about: Garmin International, Inc.
Sep 25, 2025, 08:00 ET Nobel Laureate Headlines Global Discussion in Cell & Gene Therapy in London
Joint US Head of Biopharmaceuticals Investment Banking from Jefferies, Laura Stoppel, Partner on the Investment Team, RA Capital Management, Hongbo Lu, Founder and Managing Partner of NextBio Capital and Daniela Couto,
More news about: GenScript Biotech Corporation
Sep 24, 2025, 10:00 ET GLOBAL CEOS AND GOVERNMENT LEADERS CALL FOR NEW PUBLIC-PRIVATE PARTNERSHIPS FIT FOR THE MODERN ERA AT INAUGURAL P3 SUMMIT
government, and civil society to engage in dialogue on critical issues, RA&A builds platforms that are instrumental in fostering economic growth, innovation, and greater cooperation. As a world-leading strategic communication firm, RA&A has established a reputation for empowering its clients to lead,
More news about: Teneo
Sep 24, 2025, 06:26 ET The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global Experts Call for Action on Elevated Lipoprotein(a)
Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016;57(8):1339-1359. doi:10.1194/jlr.R067314.[9] Cox RA, Garcia-Palmieri MR. Cholesterol, triglycerides, and associated lipoproteins. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History,
More news about: Global Heart Hub & Novartis